Olema Oncology to Present Preclinical Data on OP-1250, Lead Program in Breast Cancer, at ENA 2020
SAN FRANCISCO, Oct. 20, 2020 /PRNewswire/ -- Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced it will present preclinical data on the mechanism of action of OP-1250 in a poster session at the 32nd EORTC-NCI-AACR (ENA) Symposium, which will be held virtually October 24-25, 2020. OP-1250 is a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated in a Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic estrogen-receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer whose disease has progressed on endocrine therapy. Poster Presentation Details Olema plans to conduct additional studies evaluating OP-1250 in combination with other targeted breast cancer therapies. About Olema Oncology
View original content:http://www.prnewswire.com/news-releases/olema-oncology-to-present-preclinical-data-on-op-1250-lead-program-in-breast-cancer-at-ena-2020-301155028.html SOURCE Olema Pharmaceuticals, Inc |